Salesforce, Inc. (CRM) › Analysis

Salesforce, Inc. (CRM) analysis, February 24, 2026

Published February 24, 2026 · CRM chart, levels and live analysis

Key Updates

Salesforce has rebounded 3.21% to $185.72 since the February 23 report, recovering from the breakdown below $180 support and demonstrating short-term buying interest. The recovery follows a single-day 4.24% surge, though the stock remains deeply oversold with a -29.89% YTD decline. The investment thesis strengthens modestly with the $5.6 billion U.S. Army contract providing visibility into government revenue streams, though the Heroku scale-back signals portfolio rationalization that may pressure near-term growth expectations.

Current Trend

The stock exhibits severe YTD weakness with a -29.89% decline, substantially underperforming broader market indices. The 6-month trajectory shows -25.20% deterioration, while the 1-month period accelerated losses at -18.56%. The 5-day performance of +0.78% and today's +4.24% gain suggest near-term stabilization attempts, though the stock remains below the psychologically significant $190 level. The recent recovery from $179.94 to $185.72 represents a 3.21% bounce off the immediate support zone, but the broader downtrend remains intact with the stock trading well below YTD opening levels.

Investment Thesis

The investment thesis centers on Salesforce's transition to enterprise-grade AI solutions and government contract diversification, balanced against portfolio rationalization risks and competitive pressures in cloud infrastructure. The $5.6 billion U.S. Army IDIQ contract provides a 10-year revenue ceiling and validates Salesforce's positioning in national security applications through its Missionforce platform. However, the Heroku enterprise subscription discontinuation signals strategic retreat from PaaS offerings where major cloud providers dominate. The ecosystem remains vulnerable to AI-native competitors like Aurasell that promise 2x productivity improvements while integrating with existing Salesforce deployments rather than replacing them. The thesis depends on successful execution of AI Agent Builder capabilities and realization of government contract revenues offsetting legacy product pressures.

Thesis Status

The thesis shows mixed progression. The U.S. Army contract strengthens the government revenue diversification component, though the $5.6 billion represents a ceiling rather than guaranteed revenue. The Heroku scale-back confirms portfolio rationalization toward higher-margin AI solutions but raises concerns about growth trajectory compression. The emergence of AI-native competitors like Aurasell that layer on top of Salesforce rather than replacing it presents both validation of the CRM platform's stickiness and potential margin pressure from reduced feature differentiation. The -29.89% YTD decline suggests investors remain skeptical about near-term execution despite long-term contract wins.

Key Drivers

The primary positive catalyst is the $5.6 billion U.S. Army IDIQ contract awarded January 27, providing visibility into government sector expansion through Missionforce National Security capabilities supporting personnel management and operational efficiency for millions of personnel. The negative driver is the discontinuation of Heroku Enterprise Account subscriptions announced February 6, representing strategic withdrawal from competitive PaaS markets where AWS, Azure, and Google Cloud dominate. The company explicitly stated it is redirecting resources toward enterprise-grade AI solutions and areas delivering greater long-term customer value. The competitive threat intensified with Aurasell's February 12 launch of an AI-native GTM Operating System backed by $30 million in venture funding, promising 2x productivity improvements while consolidating dozens of point solutions that previously drove Salesforce ecosystem revenues.

Technical Analysis

The stock trades at $185.72, recovering 3.21% from the prior report's $179.94 level after breaking below the $180 support zone. The single-day 4.24% surge suggests short-term capitulation buying, though volume and sustainability metrics are unavailable. The $180 level now serves as immediate support following the recent test, while $190 represents near-term resistance and a psychologically significant threshold. The 5-day performance of +0.78% indicates stabilization attempts following the 1-month decline of -18.56%. The YTD decline of -29.89% places the stock in deeply oversold territory, though no clear reversal pattern has emerged. The recovery from $179.94 represents a 3.2% bounce but lacks confirmation of trend reversal given the magnitude of recent losses and absence of sustained buying pressure above $190.

Bull Case

Bear Case

Get a message when the CRM picture changes — the agent team watches the levels and the news for you.Create a free account

More CRM analyses